This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline
by Zacks Equity Research
Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline are part of today's Analyst Blog.
Top Research Reports for Pfizer, Coca-Cola & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).
Why is Viatris (VTRS) Stock Down 25% in the Year So Far?
by Zacks Equity Research
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study
by Zacks Equity Research
Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.
Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale
by Kinjel Shah
Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $49.20, marking a +0.92% move from the previous day.
Why Is Pfizer (PFE) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints
by Zacks Equity Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A
Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.
Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies
by Zacks Equity Research
Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.
Valneva (VALN) Completes Phase III Chikungunya Vaccine Study
by Zacks Equity Research
Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA
by Zacks Equity Research
The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.
AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.
WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients
by Ekta Bagri
Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.
Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine
by Zacks Equity Research
Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022
by Zacks Equity Research
Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS